|
|||||
|
|
| 克唑替尼对ALK阳性非小细胞肺癌脑转移的疗效分析 | |
| 引用本文： | 朱礼阳,许春伟,于忠和. 克唑替尼对ALK阳性非小细胞肺癌脑转移的疗效分析[J]. 国际病理科学与临床杂志, 2016, 0(9): 1293-1296. DOI: 10.3978/j.issn.2095-6959.2016.09.010 |
| 作者姓名： | 朱礼阳 许春伟 于忠和 |
| 作者单位： | 1. 陆军总医院肿瘤科,北京,100700;2. 军事医学科学院附属医院病理科,北京,100071 |
| 基金项目： | 国家自然科学基金(81372489)；北京市科技计划课题(2131100006813032)；军事医学科学院附属医院创新科研基金项目(ZH-2014-10)。@@@@This work was supported by the National Natural Science Foundation of China(81372489)，the Beijing Municipal Science and Technology Plan Project(2131100006813032)，Affliated Hospital of Academy of Military Medical Sciences Innovation Research Foundation(ZH-2014-10)，P. R. China |
| 摘 要： | 目的：非小细胞肺癌(non-small cell lung cancer，NSCLC)脑转移是影响NSCLC患者生存期及生存质量的重要因素，本研究将探讨克唑替尼在间变性淋巴瘤激酶(anaplastic lymphoma kinase， ALK)阳性NSCLC脑转移患者中的疗效。方法：筛选20例ALK阳性NSCLC脑转移患者，给予克唑替尼治疗，观察临床疗效。结果：克唑替尼治疗前基线有脑转移患者，颅内疗效部分缓解(partial response，PR)12例，疾病稳定(stable disease，SD)7例，疾病进展(progressive disease，PD)1例。客观缓解率(objective response rate，ORR)为60%，疾病控制率(disease control rate，DCR)为95%。中位无进展生存期(progression free survival，PFS)为6个月(95%CI：3.92~8.08)。结论：克唑替尼治疗ALK阳性NSCLC脑转移患者有效。 |
| 关 键 词： | 非小细胞肺癌 脑转移 间变性淋巴瘤激酶 克唑替尼 |
Efficacy analysis of crizotinib for brain metastases in ALK positive non-small cell lung cancer |
|
| Abstract: | Objective: Brain metastases have been recognized as an emerging complication in patients with anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC). This study will explore the efficacy of crizotinib in ALK-positive NSCLC with brain metastases.Methods: Selected 20 cases of brain metastatic ALK positive NSCLC patients, received crizotinib therapy to clinical observation.Results: Among patients with brain metastases before treatment, 12 had partial response (PR), 7 stable disease (SD) and 1 disease progression (PD). Objective response rate (ORR) was 60%, and disease control rate (DCR) was 95%. Median progression free survival (PFS) was 6 months (95% CI: 3.92~8.08).Conclusion: Crizotinib is effective for brain metastases in ALK positive NSCLC. |
| Keywords: | non-small cell lung cancer (NSCLC) brain metastasis anaplastic lymphoma kinase (ALK) crizotinib |
| 本文献已被 万方数据 等数据库收录！ | |